Zeekr Group Files Its 2024 Annual Report on Form 20-F
HANGZHOU, China, March 20, 2025 /PRNewswire/ -- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK), the world's leading premium new energy vehicle group, today announced that it filed its 2024 annual report on...
HUYA Inc. Announces Ex-dividend Date for Recently Announced Cash Dividend
GUANGZHOU, China, March 20, 2025 /PRNewswire/ -- HUYA Inc. ("Huya" or the "Company") (NYSE: HUYA), a leading game live streaming platform in China, today announced that the New York Stock Exchange ("NYSE") has set July 1, 2025 as the ex-dividend...
Yiren Digital Reports Fourth Quarter and Fiscal Year 2024 Financial Results
BEIJING, March 20, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE: YRD) ("Yiren Digital" or the "Company"), an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China, today announced its unaudited financial...
Tongcheng Travel Revenue Rises to RMB17.34 Billion in 2024, Adjusted Net Profit Grows 26.7% to RMB2.79 Billion
Rising Travel Spending Boosts Growth AI Integration Drives Sustainable Development HONG KONG, March 20, 2025 /PRNewswire/ -- Tongcheng Travel Holdings Limited ("Tongcheng Travel" or the "Company", together with its subsidiaries the "Group", stock...
LTP expands in Europe, acquires Spanish crypto firm Turing Capital Brokerage
MADRID, March 20, 2025 /PRNewswire/ -- LTP, a leading institutional prime brokerage specializing in digital asset markets, today announced the full acquisition of Turing Capital Brokerage ('TCB'), a Spanish brokerage firm licensed by the Bank of...
Nobu Hospitality Announces Nobu Hotel, Restaurant, and Residences Manchester and the First Residential Project in the UK
NEW YORK, March 20, 2025 /PRNewswire/ -- Nobu Hospitality, the globally recognised luxury lifestyle brand, has unveiled plans for a landmark development in Manchester, featuring a hotel, restaurant, and the UK's first Nobu-branded residences. In...
Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer
Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL The combination of golidocitinib and PD-1 antibody showed synergistic anti-tumor effects in anti-PD-1-resistant NSCLC SHANGHAI, March 20, 2025...
Baozun Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results
SHANGHAI, March 20, 2025 /PRNewswire/ -- Baozun Inc. (Nasdaq: BZUN and HKEX: 9991) ("Baozun", the "Company" or the "Group"), a leading brand e-commerce solution provider and digital commerce enabler in China, today announced its unaudited financial...